COMMITMENTS (Details) |
3 Months Ended | |||||
|---|---|---|---|---|---|---|
|
Mar. 31, 2025
USD ($)
|
Mar. 31, 2024
USD ($)
|
Dec. 31, 2024
USD ($)
|
Mar. 08, 2024
USD ($)
site
|
Feb. 01, 2024 |
Mar. 31, 2022
USD ($)
|
|
| Long-term Purchase Commitment [Line Items] | ||||||
| Lease commenced, initial period | 3 years | |||||
| Rent expense | $ 5,500 | $ 5,000 | ||||
| Research and development | 3,492,000 | 2,428,000 | ||||
| Prepaid expenses and other current assets | 458,000 | $ 393,000 | ||||
| Triple Ring Technologies | ||||||
| Long-term Purchase Commitment [Line Items] | ||||||
| Purchase commitments | $ 1,700,000 | |||||
| Research and development | 100,000 | 100,000 | ||||
| Remaining commitment | 100,000 | |||||
| Clinical Research Organization | ||||||
| Long-term Purchase Commitment [Line Items] | ||||||
| Research and development | 0 | $ 300,000 | ||||
| Amount to be paid to clinical research organization (CRO) | $ 500,000 | |||||
| Number of planned sites to carrying out the clinical study | site | 5 | |||||
| Research and development expense, expected cost | $ 900,000 | |||||
| Prepaid expenses and other current assets | $ 100,000 | |||||
| X | ||||||||||
- Definition Research And Development Expense, Expected Cost No definition available.
|
| X | ||||||||||
- Definition Research And Development, Number Of Clinical Study Sites No definition available.
|
| X | ||||||||||
- Definition Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|